Karyopharm Therapeutics(KPTI)
Focus: Karyopharm is a public biotech company focused on small-molecule oncology and hematology therapeutics, primarily advancing its lead candidate selinexor across multiple cancer indications. The company operates with 95% R&D intensity, reflecting a development-stage biotech business model.
Profile data last refreshed 14h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
1-4 this month
Stable — net -4 jobs in 30d
2 added, 6 removed. Backfill posture.
Should You Work at Karyopharm Therapeutics?
AI assessmentKaryopharm offers clinical development exposure in oncology with near-term milestones, but deteriorating cash position and selinexor-dependency present moderate restructuring risk within 12-18 months if Phase 3 programs stall.
Why Work Here
- Public company with established revenue ($146M FY2025) provides stability and equity upside potential versus early-stage biotech
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Early-stage
50 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$146M
Pipeline & Clinical Trials
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression
Polycythemia VeraClinical Trials (1)
NCT07362225MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
N/AHelp build intelligence for Karyopharm Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.